Induction therapy with antithymocyte serum (NATS) increases graft survival and function in kidneys with initial poor function.
Goldman
M H
MH
Department of Surgery, University of Tennessee Medical Center-Knoxville.
Regester
R F
RF
Freeman
M B
MB
Tyler
B
B
Tyler
J D
JD
D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006084:Graft Rejection; D006085:Graft Survival; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology / Q000502:physiology*; D012189:Retrospective Studies
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents